Sarepta Therapeutics (SRPT)
$145.61
1.83 (1.27%)
SRPT Stock Quote Delayed 30 Minutes
5 Stocks to Buy That Could Double in 2020
These are stocks with extremely high potential returns. We are talking about upside potential of over 100%. And that’s not just according to my wild calculations. That’s according to the analysts covering these stocks.
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
13.56B
PE Ratio
-24.85
EPS
-5.86
Volume (Avg. Vol.)
1.44M
Day's Range
$143.74 - $147.24
52-Week Range
$55.25 - $173.25
Dividend & Yield
N/A (N/A)
SRPT Stock Predictions, Articles, and Sarepta Therapeutics News
5 Top Stock Trades for Monday: STZ, C, UBER
STZ beat on earnings, and the Fed approved higher dividends and buybacks for the bank stocks. Here are the top stock trades heading into next week.
7 Stocks to Buy for Over 20% Upside Potential
If you’re looking for a quick portfolio boost, look no further. Here are 7 stocks to buy with tons of upside according to top analysts.
Why Sarepta Therapeutics (SRPT) Stock Is Sinking Today
Sarepta Therapeutics (SRPT) stock is sinking after the company's late Tuesday announcement that it was offering a $350 million stock ofering.
Why NOW Is the Time to Buy Gene Therapy Stocks
Over the long term, gene therapy stocks will head higher and the last few weeks' of headlines show investors why.
Why Sarepta Therapeutics Stock Is Starting to Shine Again
SRPT stock rebounded nicely from its sub-$100 low last month. More upside is possible as the Sarepta ramps up an important study.
Time to Take Some Profits in Sarepta Therapeutics Stock
Sarepta used the lobbying of patient families to win approval of a drug that may not work against Duchenne muscular dystrophy. It may be time to take profits in SRPT stock..
Why Sarepta Therapeutics Inc Stock is Sliding Today
Sarepta Therapeutics (SRPT) stock was hit hard on Friday after reports claim one of its studies was put on hold due to an adverse event.
Sarepta Therapeutics Inc (SRPT) Soars on Q2 Revenue, Forecast
Sarepta Therapeutics (SRPT) stock was flying high on Thursday following the release of its earnings report for the second quarter of 2017.
Sarepta Therapeutics Inc (SRPT) Stock Heads Higher on Analyst Upgrade
Sarepta Therapeutics Inc (SRPT) stock was up on Thursday following an upgrade and price target increase from Leerink Swann.
Buy the SPDR S&P Biotech (ETF) (XBI) TODAY – Here’s Why
Biotech stocks and the SPDR S&P Biotech ETF (XBI) just shook off a major bugaboo in Hillary Clinton. The XBI ETF will soar as a result.
24 Biotechnology Stocks to Buy Now
24 Biotechnology stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an "A" ("strong buy") or "B" overall ("buy").
